DNAPrint Genomics Stock

DNAPrint Genomics Market capitalization

The The market capitalization of DNAPrint Genomics (DNAG) as of Aug 10, 2026 is 644.61 USD.

Market capitalization

644.61USD

Last updated:

In 2026, DNAPrint Genomics's market cap stood at 644.61 USD, a % increase from the - USD market cap in the previous year.

The DNAPrint Genomics Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Capitalization (undefined USD)
Date
Market Capitalization (undefined USD)
Jan 1, 2000
0.00 base
Jan 1, 2001
0.00 base
Jan 1, 2002
0.00 base
Jan 1, 2003
0.00 base
Jan 1, 2004
0.00 base
Jan 1, 2005
0.00 base
Jan 1, 2006
0.00 base
YEARMarket Capitalization (undefined USD)
2006 -
2005 -
2004 -
2003 -
2002 -
2001 -
2000 -
Access this data via the Eulerpool API

DNAPrint Genomics Stock analysis

What does DNAPrint Genomics do? DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable. DNAPrint Genomics is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring DNAPrint Genomics's Market Capitalization

DNAPrint Genomics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of DNAPrint Genomics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

DNAPrint Genomics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in DNAPrint Genomics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about DNAPrint Genomics stock

The market capitalization of DNAPrint Genomics is 644.61 USD in 2026.

On Eulerpool you can find the complete historical development of The market capitalization DNAPrint Genomics since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's DNAPrint Genomics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — DNAPrint Genomics

All Key Metrics — DNAPrint Genomics